Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 3/20 | 1.00 |
| ▸ | TYR | P14679 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 1.00 |
| ▸ | PELI1 | Q96FA3 | 6/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyresveratrol SCHEMBL29654991 | 1.00 | TTR (1.00) | TTRCYP1A1CYP1B1ALOX5TYR | |
| Oxyresveratrol SCHEMBL988358 | 1.00 | TTR (1.00) | TTRCYP1A1CYP1B1ALOX5TYR | |
| Oxyresveratrol SCHEMBL29763087 | 1.00 | TTR (1.00) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL1822010 | 0.87 | TYR (0.75) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL1822012 | 0.87 | TYR (0.75) | TTRCYP1A1CYP1B1ALOX5TYR | |
| Oxyresveratrol SCHEMBL20584721 | 0.87 | TTR (0.75) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL12091582 | 0.85 | PTGS1 (0.74) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL1822477 | 0.85 | PTGS1 (0.74) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL30435947 | 0.85 | PTGS1 (0.74) | TTRCYP1A1CYP1B1ALOX5TYR | |
| SCHEMBL1822480 | 0.85 | PTGS1 (0.74) | TTRCYP1A1CYP1B1ALOX5TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727376-A1 | METHOD FOR ALTERING THE ALCOHOL PERCEPTION OR FLAVOUR OF A CONSUMABLE PREPARATION | Döhler GmbH (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260083663-A1 | BOTANICAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | ARKANSAS STATE UNIV JONESBORO (US) | 2026-03-26 | — | — | US | claimed |
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025264604-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | claimed |
| EP-4661836-A1 | LIQUID EXTRACT FROM SPRIGS AND/OR TWIGS OF MORUS ALBA L. AND RELATED TOPICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SKIN AGEING | Unifarco S.p.A. (IT) | 2025-12-17 | — | — | EP | claimed |
| US-20250319002-A1 | BISACURONE COMPOSITION AND METHOD OF SKIN WHITENING | Vidya Herbs, Inc. (US) | 2025-10-16 | — | — | US | claimed |
| EP-4622629-A1 | METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | Caliway Biopharmaceuticals Co. Ltd. (TW) | 2025-10-01 | — | — | EP | claimed |
| US-12431587-B2 | Composite separator including fire suppression layer containing crosslinked cyclopolyphosphazene particles and electrochemical cell including the same | GM Global Technology Operations LLC (US) | 2025-09-30 | — | — | US | claimed |
| US-20250288638-A1 | TYROSINE INHIBITORS WITH IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN NEONATAL KERATINOCYTE PROGENITORS | ESCAPE THERAPEUTICS INC (US) | 2025-09-18 | — | — | US | claimed |
| US-20020183400-A1 | Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene | L'OREAL (FR) | 2002-12-05 | — | — | US | claimed |
| EP-1234571-A1 | Topical composition containing a hydroxystilbene and a polyol | L'OREAL (FR) | 2002-08-28 | — | — | EP | claimed |
| US-6440433-B1 | TREATING MENOPAUSAL SKIN DISORDERS; APPLYING TOPICAL MIXTURE TO IMPART AGING RESISTANCE; ACTIVATING SKIN FIBROBLAST PROLIFERATION | SOCIETE L'OREAL S.A. (FR) | 2002-08-27 | — | — | US | claimed |
| EP-1068864-A1 | Use of at least a hydroxystilbene as a glycation inhibitor | L'OREAL (FR) | 2001-01-17 | — | — | EP | claimed |
| EP-1064931-A1 | Cosmetic composition containing at least an hydroxystilbene and ascorbic acid | L'OREAL (FR) | 2001-01-03 | — | — | EP | claimed |
| US-6147121-A | TOPICALLY APPLYING HYDROXYSTILBENE DERIVATIVE TO TREAT SKIN AGING AND WRINKLES | SOCIETE L'OREAL S.A. (FR) | 2000-11-14 | — | — | US | claimed |
| US-6124364-A | Desquamation/epidermal renewal of the skin and/or combating skin aging | SOCIETE L'OREAL S.A. (FR) | 2000-09-26 | — | — | US | claimed |
| EP-0953346-A1 | Use of at least a hydroxystilbebe in a skin fortifying composition | L'OREAL (FR) | 1999-11-03 | — | — | EP | claimed |
| EP-0953344-A1 | Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it | L'OREAL (FR) | 1999-11-03 | — | — | EP | claimed |
| EP-0953345-A1 | Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion | L'OREAL (FR) | 1999-11-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183400-A1 | Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene | CYP8B1, HSD17B1, HSD11B1 | TTR 3195/4885CYP1A1 171/4885CYP1B1 62/4885 |
| US-20260083663-A1 | BOTANICAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | SAMM50, SYMPK, CD69 | TTR 4880/4885CYP1A1 475/4885CYP1B1 326/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | TTR 606/4885CYP1A1 3515/4885CYP1B1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.